Cyclo Therapeutics- Warrants (14/11/2025) Overview
Valuation check: CYTHW's P/E ratio is -0.59, below the Healthcare sector average of 26.36.
Get informed when a big investor buys or sells
+ Follow-0.59
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Cyclo Therapeutics- Warrants (14/11/2025) (CYTHW) currently reports a P/E ratio of -0.59. That is below the Healthcare sector average of 26.36. Use the charts on this page to explore Cyclo Therapeutics- Warrants (14/11/2025)'s P/E ratio history and peer comparisons.
Cyclo Therapeutics- Warrants (14/11/2025)'s P/E ratio of -0.59 is lower than the Healthcare sector average of 26.36. That is roughly 102.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Cyclo Therapeutics- Warrants (14/11/2025)'s market price to a fundamental measure such as earnings, sales, or book value. At -0.59, CYTHW can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.59, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.36. From there, open related valuation or income-statement pages for Cyclo Therapeutics- Warrants (14/11/2025), and consider following CYTHW for alerts when major investors trade the stock.
Cyclo Therapeutics- Warrants (14/11/2025) is classified in the Healthcare sector. On P/E ratio, it currently shows -0.59 versus a sector average near 26.36. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTHW with unrelated industries.
